Literature DB >> 8752108

Modulation of zeta-protein kinase C by cyclic AMP in PC12 cells occurs through phosphorylation by protein kinase A.

M W Wooten1, M L Seibenhener, L H Matthews, G Zhou, E S Coleman.   

Abstract

Although cyclic AMP (cAMP) has been reported to cross talk with the protein kinase C (PKC) system, effects of elevated intracellular cAMP on the activities of specific PKC isoforms have not been studied. We report findings from a permeabilized cell assay that was used to examine changes in the activity of the atypical PKC isoforms brought about by exposure of PC12 cells to agents that elevate intracellular cAMP. We found that increases in intracellular cAMP led to rapid stimulation of atypical PKC activity, 40-70% above control, for a sustained period of time, a response that occurred independent of the phorbol 12-myristate 13-acetate (PMA)-sensitive PKC isoforms. Changes in intracellular cAMP levels resulted in a dose-dependent redistribution of zeta-PKC to the cytoplasm with a concomitant increase in the phosphorylation state of the enzyme. Incubation of purified zeta-PKC with increasing concentrations of PKA likewise caused a twofold increase in the phosphorylation state of zeta-PKC. In contrast to the positive effect that PKA-mediated phosphorylation had on the activity of zeta-PKC, the enzyme displayed reduced binding to ras when phosphorylated. Taken together, these findings are consistent with the hypothesis that protein phosphorylation of PKC acts as a positive effector of its enzyme activity and may serve as a negative modulator for interaction with other proteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752108     DOI: 10.1046/j.1471-4159.1996.67031023.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  MEK5, a new target of the atypical protein kinase C isoforms in mitogenic signaling.

Authors:  M T Diaz-Meco; J Moscat
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  Characterization of a Madin-Darby canine kidney cell line stably expressing TRPV5.

Authors:  Els den Dekker; Joost Schoeber; Catalin N Topala; Stan F J van de Graaf; Joost G J Hoenderop; René J M Bindels
Journal:  Pflugers Arch       Date:  2005-05-28       Impact factor: 3.657

3.  Regulation of catalase enzyme activity by cell signaling molecules.

Authors:  Sumio Yano; Noriko Yano
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

4.  Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade.

Authors:  E Berra; M M Municio; L Sanz; S Frutos; M T Diaz-Meco; J Moscat
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

5.  Localization of atypical protein kinase C isoforms into lysosome-targeted endosomes through interaction with p62.

Authors:  P Sanchez; G De Carcer; I V Sandoval; J Moscat; M T Diaz-Meco
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

6.  Roles of atypical protein kinase C in lysophosphatidic acid-induced type II adenylyl cyclase activation in RAW 264.7 macrophages.

Authors:  W W Lin; S H Chang; S M Wang
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

7.  β-Adrenergic receptors stimulate interleukin-6 production through Epac-dependent activation of PKCδ/p38 MAPK signalling in neonatal mouse cardiac fibroblasts.

Authors:  Chao Chen; Jianhai Du; Wei Feng; Yao Song; Zhizhen Lu; Ming Xu; Zijian Li; Youyi Zhang
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

8.  Par-4: a new activator of myosin phosphatase.

Authors:  Susanne Vetterkind; Eunhee Lee; Eric Sundberg; Ransom H Poythress; Terence C Tao; Ute Preuss; Kathleen G Morgan
Journal:  Mol Biol Cell       Date:  2010-02-03       Impact factor: 4.138

9.  Angiotensin II AT1 receptor stimulates Na+ -K+ATPase activity through a pathway involving PKC-zeta in rat thyroid cells.

Authors:  S Marsigliante; A Muscella; M G Elia; S Greco; C Storelli
Journal:  J Physiol       Date:  2003-01-15       Impact factor: 5.182

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.